A Methodology for Assessing Treatment Response in Hashimoto’s Encephalopathy: A Case Study Demonstrating Repeated Computerized Neuropsychological Testing

Abstract

Hashimoto’s encephalopathy, a steroid-responsive encephalopathy, presents with cognitive deterioration, psychiatric symptoms, and seizures and is often associated with elevation of anti—thyroid peroxidase antibodies or thyroid dysfunction. Because of the absence of a gold-standard diagnostic test and serological marker of disease, improvement in cognitive impairment is an important sign when assessing response to corticosteroid treatment. The purpose of this case study is to present a methodology for tracking neurocognitive functioning using computerized testing (CNS Vital Signs) in a 14-year-old girl with Hashimoto’s encephalopathy. Computerized neuropsychological testing was done prior to commencing corticosteroid treatment, as well as at 7 follow-up assessments over 1 year. Improvement in cognitive, psychological, and behavioral functioning heralded a response to treatment, which was sustained during tapering of medication. Computerized neuropsychological testing seems to be a viable tool for tracking cognitive functioning (when rapid assessments are desired) and assessing response to corticosteroid treatment in Hashimoto’s encephalopathy.

Keywords

autoimmune thyroid neuropsychology computer assessment outcome

Get full access to this article

View all access options for this article.

References

Ferraci F. , Bertiago G. , Moretto G. Hashimoto’s encephalopathy: epidemiologic data and pathogenetic considerations . J Neurol Sci. 2004;217:165-168.

Mocellin R. , Walterfang M. , Velakoulis D. Hashimoto’s encephalopathy: epidemiology, pathogenesis and management . CNS Drugs. 2007;21:799-811.

Cummings RR , Bagley SC , Syed S. , et al. Hashimoto’s encephalopathy: a case report with neuropsychological testing. Gen Hosp Psychiatry. 2007;29:267-269.

Gayatri NA , Whitehouse WP Pilot survey of Hashimoto’s encephalopathy in children. Dev Med Child Neurol. 2005;47:556-558.

Gucuyener K. , Serdaroglu A. , Bideci A. , et al. Tremor and myoclonus heralding Hashimoto’s encephalopathy. J Pediatr Endocrinol Metab. 2000;13:1137-1141.

Janes SE , Santosh B. , Thomas D. , Vyas H. Hashimoto’s encephalopathy: an unusual cause of seizures in the intensive care unit. Pediatr Crit Care Med. 2004;5:578-581.

Vasconcellos E. , Pina-Garza JE , Fakhoury T. , Fenichel GM Pediatric manifestations of Hashimoto’s encephalopathy. Pediatr Neurol. 1999;20:394-398.

Kothbauer-Margreiter I. , Sturzenegger M. , Komor J. , et al. Encephalopathy associated with Hashimoto’s thyroiditis: diagnosis and treatment. J Neurol. 1996;243:585-593.

Jacob S. , Rajabally YA Hashimoto’s encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry. 2005;76:455-456.

10.

Gualtieri CT , Johnson LG Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol . 2006;21:623-643.

11.

Brooks BL , Iverson GL , Sherman EM , Roberge MC Identifying cognitive problems in children and adolescents with depression using computerized neuropsychological testing. Appl Neuropsychol . 2010;17:37-43.

12.

Gualtieri CT , Johnson LG Efficient allocation of attentional resources in patients with ADHD: maturational changes from age 10 to 29. J Atten Disord. 2006;9:534-542.

13.

Jacobson NS , Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12-19.

14.

Byrne OC , Zuberi SM , Madigan CA , King MD Hashimoto’s thyroiditis: a rare but treatable cause of encephalopathy in children. Eur J Paediatr Neurol. 2000;4:279-282.

15.

Huang CW , Pai MC , Tsai JJ Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatry Clin Neurosci. 2008;62:548-553.